Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEREGRINE: Brolucizumab Switch and Extend in nAMD
NCT04697953Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
Phase 3, open-label, single-arm trial of brolucizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Primary endpoint: Proportion of patients successfully extending dosing interval without disease activity at 52 weeks. Planned start May 2021; status: withdrawn.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04697953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04697953.